CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,923,078
- in 11 filings, $11.2M under 10b5-1 plans
Net −$33,923,078. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-04 | Weiss Amir Chief Accounting Officer | Option exercise | +5,650 | 27,158 | ||
| 2026-03-04 | Weiss Amir Chief Accounting Officer | Option exercise · Restricted Share Units | −10,679 | 0 | ||
| 2026-03-04 | Weiss Amir Chief Accounting Officer | Option exercise · Restricted Share Units | −5,650 | 11,300 | ||
| 2026-03-04 | Weiss Amir Chief Accounting Officer | Grant or award · Restricted Share Units | +11,280 | 11,280 | ||
| 2026-03-03 | Weiss Amir Chief Accounting Officer | Option exercise | +5,179 | 10,829 | ||
| 2026-03-03 | Weiss Amir Chief Accounting Officer | Option exercise · Restricted Share Units | −5,179 | 5,180 | ||
| 2026-03-03 | Daniell Richard EVP, Europe Commercial | Option exercise 10b5-1 | +62,250 | 110,634 | ||
| 2026-03-03 | Daniell Richard EVP, Europe Commercial | Sale 10b5-1 | −62,250 | $32.36 | $2.0M | 48,384 |
| 2026-03-03 | Daniell Richard EVP, Europe Commercial | Option exercise 10b5-1 | +141,478 | 189,862 | ||
| 2026-03-03 | Daniell Richard EVP, Europe Commercial | Sale 10b5-1 | −66,735 | $32.36 | $2.2M | 123,127 |
| 2026-03-03 | Daniell Richard EVP, Europe Commercial | Option exercise · Restricted Share Units 10b5-1 | −62,250 | 62,253 | ||
| 2026-03-03 | Daniell Richard EVP, Europe Commercial | Option exercise · Restricted Share Units 10b5-1 | −141,478 | 0 | ||
| 2026-03-03 | Sabag Mark See "Remarks" | Option exercise | +24,900 | 77,728 | ||
| 2026-03-03 | Sabag Mark See "Remarks" | Option exercise | +141,478 | 219,206 | ||
| 2026-03-03 | Sabag Mark See "Remarks" | Option exercise · Restricted Share Units | −24,900 | 24,901 | ||
| 2026-03-03 | Sabag Mark See "Remarks" | Option exercise · Restricted Share Units | −141,478 | 0 | ||
| 2026-03-03 | Savage Brian Interim Chief Legal Officer | Option exercise | +3,461 | 4,200 | ||
| 2026-03-03 | Savage Brian Interim Chief Legal Officer | Sale | −1,274 | $32.36 | $41K | 2,926 |
| 2026-03-03 | Savage Brian Interim Chief Legal Officer | Option exercise · Restricted Share Units | −3,461 | 3,461 | ||
| 2026-03-03 | Francis Richard D President and CEO | Option exercise 10b5-1 | +67,231 | 673,002 |
Page 9 of 64 · 1,279 trades